HALO vs MOH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HALO presents a stark contrast between operational efficiency and valuation sanity. While the Piotroski F-Score of 4/9 indicates stable financial health, the stock trades at a massive premium to its Graham Number ($4.88) and Intrinsic Value ($17.92). Despite exceptional operating margins (56.31%) and strong revenue growth (51.6%), the recent collapse in EPS (-114% Q/Q) and aggressive insider selling by the CEO and COO create significant headwinds that offset the bullish analyst consensus.
Molina Healthcare exhibits a stable Piotroski F-Score of 5/9, but this is overshadowed by a severe collapse in profitability and earnings quality. The company is currently trading at $151.00, which is significantly above its growth-based intrinsic value of $62.79 and its defensive Graham Number of $126.90. A rising Medical Care Ratio (MCR) of 91.7% and negative operating margins (-1.49%) indicate that rising healthcare costs are outpacing state reimbursement rates. With a 1-year price decline of 50% and a catastrophic YoY EPS growth of -154.5%, the stock appears to be in a fundamental downtrend.
Compare Another Pair
Related Comparisons
HALO vs MOH: Head-to-Head Comparison
This page compares Halozyme Therapeutics, Inc. (HALO) and Molina Healthcare, Inc. (MOH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.